Multi-Center Study of the Effect of Sevelamer Carbonate (Renvela) on Metabolic/Inflammatory/ROS in Diabetics With Nephropathy

Trial Profile

Multi-Center Study of the Effect of Sevelamer Carbonate (Renvela) on Metabolic/Inflammatory/ROS in Diabetics With Nephropathy

Completed
Phase of Trial: Phase II

Latest Information Update: 07 May 2015

At a glance

  • Drugs Sevelamer (Primary) ; Calcium carbonate
  • Indications Diabetic nephropathies
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Apr 2014 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
    • 31 May 2012 Actual initiation date (February 2012) added as reported by ClinicalTrials.gov.
    • 31 May 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top